In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering the recent data from the ARANOTE study.
Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, discusses some of the most promising findings from the EPIC-A trial of cemiplimab with chemotherapy in treating locally advanced or metastatic penile ...
The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...
Panelists discuss how incorporating both neoadjuvant and adjuvant treatment approaches into clinical trial designs has shown promising improvements in event-free survival outcomes across multiple ...
Panelists discuss how recent clinical data presented at ASCO 2025 showed varying results across primary endpoints including overall survival, progression-free survival, efficacy measures, and safety ...
The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...
The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, ...
Marlise R. Luskin, MD, MSCE, discusses the trial of tagraxofusp in BPDCN, which showed high response rates and overall survival.
Alexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study.
An expert discusses the design and objectives of the PEACE-3 study, which investigates the combination of enzalutamide and ...
IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...